Impax adds TetraLogic Pharmaceuticals CEO to board

HAYWARD, Calif. — Impax Laboratories has a new board member. The company announced Monday that it had appointed J. Kevin Buchi, CEO of TetraLogic Pharmaceuticals, to its board of directors. 

 

“We are pleased to welcome Kevin to our Board,” Impax chairman Robert L. Burr said. “Kevin brings a great deal of pharmaceutical experience as an accomplished executive and director. He will provide valuable insights and perspective with respect to our operations, strategy and corporate governance.”

 

Before joining TetraLogic Pharmaceuticals in 2013, Buchi was Teva’s corporate VP global branded products, and before that was CEO of Cephalon, which Teva acquired in October 2011. He had been with Cephalon since 1991 in various leadership positions, including CFO and COO before being appointed CEO in 2010. He also is a board member at Benitec Biopharma and has previously served on the boards of EPIRUS Biopharmaceuticals, Alexza Pharmaceuticals and Forward Pharma.